Frequency of Neurologic Manifestations in COVID-19: A Systematic Review and Meta-analysis.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
07 12 2021
07 12 2021
Historique:
received:
05
05
2021
accepted:
30
09
2021
pubmed:
13
10
2021
medline:
18
12
2021
entrez:
12
10
2021
Statut:
ppublish
Résumé
One year after the onset of the coronavirus disease 2019 (COVID-19) pandemic, we aimed to summarize the frequency of neurologic manifestations reported in patients with COVID-19 and to investigate the association of these manifestations with disease severity and mortality. We searched PubMed, Medline, Cochrane library, ClinicalTrials.gov, and EMBASE for studies from December 31, 2019, to December 15, 2020, enrolling consecutive patients with COVID-19 presenting with neurologic manifestations. Risk of bias was examined with the Joanna Briggs Institute scale. A random-effects meta-analysis was performed, and pooled prevalence and 95% confidence intervals (CIs) were calculated for neurologic manifestations. Odds ratio (ORs) and 95% CIs were calculated to determine the association of neurologic manifestations with disease severity and mortality. Presence of heterogeneity was assessed with Of 2,455 citations, 350 studies were included in this review, providing data on 145,721 patients with COVID-19, 89% of whom were hospitalized. Forty-one neurologic manifestations (24 symptoms and 17 diagnoses) were identified. Pooled prevalence of the most common neurologic symptoms included fatigue (32%), myalgia (20%), taste impairment (21%), smell impairment (19%), and headache (13%). A low risk of bias was observed in 85% of studies; studies with higher risk of bias yielded higher prevalence estimates. Stroke was the most common neurologic diagnosis (pooled prevalence 2%). In patients with COVID-19 ≥60 years of age, the pooled prevalence of acute confusion/delirium was 34%, and the presence of any neurologic manifestations in this age group was associated with mortality (OR 1.80, 95% CI 1.11-2.91). Up to one-third of patients with COVID-19 analyzed in this review experienced at least 1 neurologic manifestation. One in 50 patients experienced stroke. In those >60 years of age, more than one-third had acute confusion/delirium; the presence of neurologic manifestations in this group was associated with nearly a doubling of mortality. Results must be interpreted with the limitations of observational studies and associated bias in mind. PROSPERO CRD42020181867.
Sections du résumé
BACKGROUND AND OBJECTIVES
One year after the onset of the coronavirus disease 2019 (COVID-19) pandemic, we aimed to summarize the frequency of neurologic manifestations reported in patients with COVID-19 and to investigate the association of these manifestations with disease severity and mortality.
METHODS
We searched PubMed, Medline, Cochrane library, ClinicalTrials.gov, and EMBASE for studies from December 31, 2019, to December 15, 2020, enrolling consecutive patients with COVID-19 presenting with neurologic manifestations. Risk of bias was examined with the Joanna Briggs Institute scale. A random-effects meta-analysis was performed, and pooled prevalence and 95% confidence intervals (CIs) were calculated for neurologic manifestations. Odds ratio (ORs) and 95% CIs were calculated to determine the association of neurologic manifestations with disease severity and mortality. Presence of heterogeneity was assessed with
RESULTS
Of 2,455 citations, 350 studies were included in this review, providing data on 145,721 patients with COVID-19, 89% of whom were hospitalized. Forty-one neurologic manifestations (24 symptoms and 17 diagnoses) were identified. Pooled prevalence of the most common neurologic symptoms included fatigue (32%), myalgia (20%), taste impairment (21%), smell impairment (19%), and headache (13%). A low risk of bias was observed in 85% of studies; studies with higher risk of bias yielded higher prevalence estimates. Stroke was the most common neurologic diagnosis (pooled prevalence 2%). In patients with COVID-19 ≥60 years of age, the pooled prevalence of acute confusion/delirium was 34%, and the presence of any neurologic manifestations in this age group was associated with mortality (OR 1.80, 95% CI 1.11-2.91).
DISCUSSION
Up to one-third of patients with COVID-19 analyzed in this review experienced at least 1 neurologic manifestation. One in 50 patients experienced stroke. In those >60 years of age, more than one-third had acute confusion/delirium; the presence of neurologic manifestations in this group was associated with nearly a doubling of mortality. Results must be interpreted with the limitations of observational studies and associated bias in mind.
SYSTEMATIC REVIEW REGISTRATION
PROSPERO CRD42020181867.
Identifiants
pubmed: 34635561
pii: WNL.0000000000012930
doi: 10.1212/WNL.0000000000012930
pmc: PMC8665434
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2269-e2281Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NCATS NIH HHS
ID : UL1 TR001857
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS113037
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS096714
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 American Academy of Neurology.
Références
Neurology. 2020 Dec 15;95(24):e3373-e3385
pubmed: 32934172
Sci Rep. 2020 Nov 13;10(1):19765
pubmed: 33188232
Trends Neurosci. 2014 Jan;37(1):39-46
pubmed: 24239063
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
Biometrics. 2000 Jun;56(2):455-63
pubmed: 10877304
JAMA Neurol. 2020 Jul 2;:
pubmed: 32614385
J Intern Med. 2021 Aug;290(2):451-461
pubmed: 33403772
Neurol Sci. 2020 Dec;41(12):3437-3470
pubmed: 33089477
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
N Engl J Med. 2020 Jun 4;382(23):2268-2270
pubmed: 32294339
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Lancet Neurol. 2020 Sep;19(9):767-783
pubmed: 32622375
ACS Chem Neurosci. 2020 Apr 1;11(7):995-998
pubmed: 32167747
Front Neurol. 2020 Jun 26;11:687
pubmed: 32676052
Front Neurol. 2020 May 29;11:565
pubmed: 32574250
Ann Clin Transl Neurol. 2020 Nov;7(11):2221-2230
pubmed: 33016619
PLoS One. 2015 Sep 30;10(9):e0139030
pubmed: 26422698
eNeurologicalSci. 2020 Dec;21:100287
pubmed: 33163634
Brain. 2012 Sep;135(Pt 9):2809-16
pubmed: 22879644
Gen Hosp Psychiatry. 2020 Jul - Aug;65:47-53
pubmed: 32470824
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Clin Neurol Neurosurg. 2021 Jan;200:106349
pubmed: 33172719
JBI Evid Synth. 2020 Oct;18(10):2127-2133
pubmed: 33038125
Int Forum Allergy Rhinol. 2020 Jul;10(7):821-831
pubmed: 32329222
N Engl J Med. 2020 May 14;382(20):e60
pubmed: 32343504
Arch Intern Med. 2002 Feb 25;162(4):457-63
pubmed: 11863480
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288